If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 4 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Mesothelioma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Survival Medicine & Life Sciences
Cell Line Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2004 2020

Pharmacokinetics
Safety
Drug Therapy
Pharmaceutical Preparations
Neoplasms

A Phase IB Study of Crizotinib in Combi

Kratzke, R. A.

PFIZER, INC.

11/20/157/30/20

Project: Research project

Non-Small Cell Lung Carcinoma
crizotinib
pembrolizumab
Punicaceae
Prostate-Specific Antigen
Prostate
Therapeutics
docetaxel
Prednisone
Prostatic Neoplasms
Hormones
Drug Therapy
Punicaceae
Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Placebos

Research Output 1987 2019

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion

Alharbi, A. F., Kratzke, R. A., D’Cunha, J., Maddaus, M. A., Sanghavi, K. J. & Kirstein, M. N., Feb 5 2019, In : Cancer chemotherapy and pharmacology. 83, 2, p. 387-391 5 p.

Research output: Contribution to journalArticle

gemcitabine
Bronchial Arteries
Pharmacokinetics
Metabolites
Intravenous Infusions

Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer

De, A., Jacobson, B. A., Peterson, M. S., Stelzner, M. E., Jay-Dixon, J., Kratzke, M. G., Patel, M. R., Bitterman, P. B. & Kratzke, R. A., May 1 2019, In : Cancer gene therapy. 26, 5-6, p. 157-165 9 p.

Research output: Contribution to journalArticle

Eukaryotic Initiation Factor-4F
Non-Small Cell Lung Carcinoma
Genome
Growth
gemcitabine

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

Patel, M. R., Dash, A., Jacobson, B. A., Ji, Y., Baumann, D., Ismail, K. & Kratzke, R. A., Jan 1 2019, (Accepted/In press) In : Cancer Gene Therapy.

Research output: Contribution to journalArticle

Oncolytic Virotherapy
Vesicular Stomatitis
Non-Small Cell Lung Carcinoma
Interferons
Viruses
1 Citation (Scopus)

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

LACE-Bio Steering Committee, Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 66-73.e6

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Biomarkers
Immunohistochemistry
Patient Selection
Adjuvant Chemotherapy
2 Citations (Scopus)

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

De, A., Jacobson, B. A., Peterson, M. S., Jay-Dixon, J., Kratzke, M. G., Sadiq, A. A., Patel, M. R. & Kratzke, R. A., Apr 1 2018, In : Investigational New Drugs. 36, 2, p. 217-229 13 p.

Research output: Contribution to journalArticle

Eukaryotic Initiation Factor-4F
Genome
gemcitabine
Pemetrexed
Osteopontin